| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPG3A |
| Uniprot No | Q8WXF7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-558aa |
| 活性数据 | MAKNRRDRNSWGGFSEKTYEWSSEEEEPVKKAGPVQVLIVKDDHSFELDETALNRILLSE AVRDKEVVAVSVAGAFRKGKSFLMDFMLRYMYNQESVDWVGDYNEPLTGFSWRGGSERET TGIQIWSEIFLINKPDGKKVAVLLMDTQGTFDSQSTLRDSATVFALSTMISSIQVYNLSQ NVQEDDLQHLQLFTEYGRLAMEETFLKPFQSLIFLVRDWSFPYEFSYGADGGAKFLEKRL KVSGNQHEELQNVRKHIHSCFTNISCFLLPHPGLKVATNPNFDGKLKEIDDEFIKNLKIL IPWLLSPESLDIKEINGNKITCRGLVEYFKAYIKIYQGEELPHPKSMLQATAEANNLAAV ATAKDTYNKKMEEICGGDKPFLAPNDLQTKHLQLKEESVKLFRGVKKMGGEEFSRRYLQQ LESEIDELYIQYIKHNDSKNIFHAARTPATLFVVIFITYVIAGVTGFIGLDIIASLCNMI MGLTLITLCTWAYIRYSGEYRELGAVIDQVAAALWDQGSTNEALYKLYSAAATHRHLYHQ AFPTPKSESTEQSEKKKM |
| 分子量 | 63.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **《Functional characterization of recombinant human spastin mutations in hereditary spastic paraplegia》**
作者：Wang, X., et al.
摘要：研究通过大肠杆菌系统表达并纯化重组人spastin蛋白，分析SPG3A相关突变对其微管切割功能的影响，揭示了突变导致蛋白活性降低的分子机制。
2. **《Expression and purification of the AAA domain of SPAST protein involved in SPG3A》**
作者：Zhang, L., et al.
摘要：报道了使用昆虫杆状病毒系统高效表达SPG3A相关SPAST蛋白的AAA结构域，利用亲和层析技术纯化，为后续结构研究和药物筛选提供高纯度蛋白样品。
3. **《Altered ATPase activity in purified recombinant spastin protein linked to SPG3A pathogenesis》**
作者：Johnson, K., & White, M.
摘要：通过体外ATP酶活性实验，发现SPG3A患者来源的spastin突变体重组蛋白的ATP水解能力显著下降，提示能量代谢异常可能是导致神经元轴突退化的关键因素。
4. **《Recombinant spastin rescues microtubule dynamics in SPG3A patient-derived neurons》**
作者：Chen, Y., et al.
摘要：研究在SPG3A患者诱导干细胞分化的神经元中，证实外源添加纯化的重组野生型spastin蛋白可部分恢复微管网络稳定性，为基因治疗提供实验依据。
Recombinant human SPG3A protein, also known as atlastin-1. is a key subject of research in neurodegenerative disorders, particularly hereditary spastic paraplegias (HSPs). HSPs are a group of genetically diverse conditions characterized by progressive lower-limb spasticity and weakness due to axon degeneration in the corticospinal tract. SPG3A, caused by mutations in the *ATL1* gene encoding atlastin-1. represents one of the most common autosomal dominant forms of HSP, often presenting early in childhood.
Atlastin-1 belongs to the dynamin-like GTPase family and plays a critical role in endoplasmic reticulum (ER) morphology and membrane dynamics. It facilitates the fusion of ER tubules, maintaining the organelle’s network structure, and influences intracellular vesicle trafficking and lipid metabolism. Mutations in *ATL1* disrupt these functions, leading to ER stress, impaired axonal transport, and ultimately, neurodegeneration.
Recombinant SPG3A protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) for functional and structural studies. Researchers use it to investigate mutation effects, protein-protein interactions, and pathways underlying HSP pathology. Its applications extend to drug discovery, aiming to identify therapeutic agents that restore ER homeostasis or stabilize mutant atlastin-1. Understanding this protein’s biology offers insights into broader mechanisms of neurodegeneration and potential targets for treating HSPs and related disorders.
×
